Morphine Use in Renal Failure: A Case Report of Single-Dose Morphine Toxicity in a Patient Requiring Peritoneal Dialysis

Abstract

Objective:

We describe a case of morphine toxicity presumably caused by accumulation of its active metabolite morphine-6-glucuronide (M6G) secondary to reduced clearance by peritoneal dialysis.

Methods:

We present the relevant history and laboratory data and review pertinent literature regarding the use of opioids in renal failure.

Results:

A 76-year-old African-American female received one dose of morphine sulfate and developed signs and symptoms of morphine toxicity for 2 days, even after multiple peritoneal dialysis sessions.

Conclusion:

Because of reduced renal clearance of morphine and its metabolites in patients requiring peritoneal dialysis, morphine should be avoided as an analgesic option in this population due to increased risk of morphine toxicity.

Keywords

peritoneal dialysis M6G morphine toxicity morphine renal clearance hospice

Get full access to this article

View all access options for this article.

References

Pauli-Magnus

Hofmann

Mikus

, et al. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1999;14(4):903–909.

Dean

. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497–504.

Naranjo

Busto

Sellers

, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.

Angst

Buhrer

Lotsch

. Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. Anesthesiology. 2000;92(5):1473–1476.

Ishida

McCulloch

Steinman

, et al. Opioid analgesics and adverse outcomes among hemodialysis patients. Clin J Am Nephril. 2018;13(5):746–753.

Coalition for Supportive Care of Kidney Patients: Treating pain in advanced CKD and dialysis patients: Clinical algorithm and preferred medications, 2016. Accessed Aug 21, 2018. http://www.kidneysupportivecare.org/Files/TreatingPaininLateCKD11-2016.aspx

Davison

. The prevalence and management of chronic pain in end-stage renal disease. J Palliat Med. 2007;10(6):1277–1287.

Barakzoy

Moss

. Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease. J Am Soc Nephrol. 2006;17(11):3198–3203.

Lee

Leng

Tiernan

. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med. 2001;15(1):26–34.